Review



body weight cb 839  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 96

    Structured Review

    MedChemExpress body weight cb 839
    a , Schematic of [1,2- 13 C]- d -glucose tracing in glycolysis (blue circles) or the pentose phosphate pathway (PPP) (grey circles). b , c , Fractions of labelled pyruvate ( b ) and lactate ( c ) from [1,2- 13 C]- d -glucose in KP -Y and KP -O ( n = 6). d , Schematic of [U 13 C]- l -glutamine tracing (pink circles). e , Mass isotopomer analysis of glutamate (Glu), fumarate (Fum), citrate (Cit) and aspartate (Asp) from [U 13 C]- l -glutamine tracing in KP -Y ( n = 6) and KP -O ( n = 4). f , g , Oxygen consumption rate (OCR) ( f ) and extracellular acidification rate (ECAR) ( g ) in KP -Y ( n = 10) and KP -O ( n = 11). h , i , Mass isotopomer analysis of indicated TCA intermediates from [U 13 C]- l -glutamine tracing in KP -Y, KP -O, KP -Y sh Atf4 .2, KP -O sh Atf4 .2 ( h ) and in KP -Y; KP -Y ATF4 o/e; KP -O and KP -O ATF4 o/e ( i ) ( n = 4 per condition). j , Relative viability of KP -Y and KP -O treated <t>with</t> <t>CB-839</t> ( n = 3) k , Heatmap of relative viability for KP -Y and KP -O treated with 0.1 μM CB-839 and the indicated compounds. All data points are relative to vehicle (Veh)-treated controls ( n = 3). l , Anoikis resistance of KP -Y; KP -Y ATF4 o/e; KP -O and KP -O ATF4 o/e treated with 0.1 μM CB-839 for 48 h ( n = 3). m , Heatmap of anoikis resistance of KP -Y and KP -O treated with 0.1 μM CB-839 and the indicated compounds. All data points are relative to vehicle-treated controls ( n = 3). n , o , Lung metastasis burden measured by means of bioluminescence ( n ) or H&E quantification ( o ) (with representative images) in mice after intravenous injections of KP -Y and KP -O and treated with CB-839 or vehicle ( n = 4, 3, 4, 5). p , q , Longitudinal tumour growth of subcutaneous tumours ( KP -Y n = 24, KP -Y + CB-839 n = 22, KP -O n = 26 and KP -O + CB-839 n = 18 tumours) ( p ) and H&E quantification of lung metastases foci ( n = 12, 11, 13 and 9 mice, respectively) ( q ). Mice were administered CB-839 once the tumours reached 100 mm 3 in size. Data are mean ± s.e.m. Two-sided multiple unpaired t -tests ( b , c , e – i , q ), two-way ANOVA ( j , p ), one-way ANOVA with Tukey’s multiple comparisons test ( l , n , o ). 5ME-THF, 5-methyltetrahydrofolate; NAC, N -acetyl- l -cysteine; NEAA, non-essential amino acids; NS, not significant. Scale bars, 1 mm.
    Body Weight Cb 839, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 96/100, based on 133 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/body+weight+cb+839/Telaglenastat/pmc13128440-218-16-21
    Average 96 stars, based on 133 article reviews
    body weight cb 839 - by Bioz Stars, 2026-09
    96/100 stars

    Images

    1) Product Images from "Ageing promotes metastasis via activation of the integrated stress response"

    Article Title: Ageing promotes metastasis via activation of the integrated stress response

    Journal: Nature

    doi: 10.1038/s41586-026-10216-0

    a , Schematic of [1,2- 13 C]- d -glucose tracing in glycolysis (blue circles) or the pentose phosphate pathway (PPP) (grey circles). b , c , Fractions of labelled pyruvate ( b ) and lactate ( c ) from [1,2- 13 C]- d -glucose in KP -Y and KP -O ( n = 6). d , Schematic of [U 13 C]- l -glutamine tracing (pink circles). e , Mass isotopomer analysis of glutamate (Glu), fumarate (Fum), citrate (Cit) and aspartate (Asp) from [U 13 C]- l -glutamine tracing in KP -Y ( n = 6) and KP -O ( n = 4). f , g , Oxygen consumption rate (OCR) ( f ) and extracellular acidification rate (ECAR) ( g ) in KP -Y ( n = 10) and KP -O ( n = 11). h , i , Mass isotopomer analysis of indicated TCA intermediates from [U 13 C]- l -glutamine tracing in KP -Y, KP -O, KP -Y sh Atf4 .2, KP -O sh Atf4 .2 ( h ) and in KP -Y; KP -Y ATF4 o/e; KP -O and KP -O ATF4 o/e ( i ) ( n = 4 per condition). j , Relative viability of KP -Y and KP -O treated with CB-839 ( n = 3) k , Heatmap of relative viability for KP -Y and KP -O treated with 0.1 μM CB-839 and the indicated compounds. All data points are relative to vehicle (Veh)-treated controls ( n = 3). l , Anoikis resistance of KP -Y; KP -Y ATF4 o/e; KP -O and KP -O ATF4 o/e treated with 0.1 μM CB-839 for 48 h ( n = 3). m , Heatmap of anoikis resistance of KP -Y and KP -O treated with 0.1 μM CB-839 and the indicated compounds. All data points are relative to vehicle-treated controls ( n = 3). n , o , Lung metastasis burden measured by means of bioluminescence ( n ) or H&E quantification ( o ) (with representative images) in mice after intravenous injections of KP -Y and KP -O and treated with CB-839 or vehicle ( n = 4, 3, 4, 5). p , q , Longitudinal tumour growth of subcutaneous tumours ( KP -Y n = 24, KP -Y + CB-839 n = 22, KP -O n = 26 and KP -O + CB-839 n = 18 tumours) ( p ) and H&E quantification of lung metastases foci ( n = 12, 11, 13 and 9 mice, respectively) ( q ). Mice were administered CB-839 once the tumours reached 100 mm 3 in size. Data are mean ± s.e.m. Two-sided multiple unpaired t -tests ( b , c , e – i , q ), two-way ANOVA ( j , p ), one-way ANOVA with Tukey’s multiple comparisons test ( l , n , o ). 5ME-THF, 5-methyltetrahydrofolate; NAC, N -acetyl- l -cysteine; NEAA, non-essential amino acids; NS, not significant. Scale bars, 1 mm.
    Figure Legend Snippet: a , Schematic of [1,2- 13 C]- d -glucose tracing in glycolysis (blue circles) or the pentose phosphate pathway (PPP) (grey circles). b , c , Fractions of labelled pyruvate ( b ) and lactate ( c ) from [1,2- 13 C]- d -glucose in KP -Y and KP -O ( n = 6). d , Schematic of [U 13 C]- l -glutamine tracing (pink circles). e , Mass isotopomer analysis of glutamate (Glu), fumarate (Fum), citrate (Cit) and aspartate (Asp) from [U 13 C]- l -glutamine tracing in KP -Y ( n = 6) and KP -O ( n = 4). f , g , Oxygen consumption rate (OCR) ( f ) and extracellular acidification rate (ECAR) ( g ) in KP -Y ( n = 10) and KP -O ( n = 11). h , i , Mass isotopomer analysis of indicated TCA intermediates from [U 13 C]- l -glutamine tracing in KP -Y, KP -O, KP -Y sh Atf4 .2, KP -O sh Atf4 .2 ( h ) and in KP -Y; KP -Y ATF4 o/e; KP -O and KP -O ATF4 o/e ( i ) ( n = 4 per condition). j , Relative viability of KP -Y and KP -O treated with CB-839 ( n = 3) k , Heatmap of relative viability for KP -Y and KP -O treated with 0.1 μM CB-839 and the indicated compounds. All data points are relative to vehicle (Veh)-treated controls ( n = 3). l , Anoikis resistance of KP -Y; KP -Y ATF4 o/e; KP -O and KP -O ATF4 o/e treated with 0.1 μM CB-839 for 48 h ( n = 3). m , Heatmap of anoikis resistance of KP -Y and KP -O treated with 0.1 μM CB-839 and the indicated compounds. All data points are relative to vehicle-treated controls ( n = 3). n , o , Lung metastasis burden measured by means of bioluminescence ( n ) or H&E quantification ( o ) (with representative images) in mice after intravenous injections of KP -Y and KP -O and treated with CB-839 or vehicle ( n = 4, 3, 4, 5). p , q , Longitudinal tumour growth of subcutaneous tumours ( KP -Y n = 24, KP -Y + CB-839 n = 22, KP -O n = 26 and KP -O + CB-839 n = 18 tumours) ( p ) and H&E quantification of lung metastases foci ( n = 12, 11, 13 and 9 mice, respectively) ( q ). Mice were administered CB-839 once the tumours reached 100 mm 3 in size. Data are mean ± s.e.m. Two-sided multiple unpaired t -tests ( b , c , e – i , q ), two-way ANOVA ( j , p ), one-way ANOVA with Tukey’s multiple comparisons test ( l , n , o ). 5ME-THF, 5-methyltetrahydrofolate; NAC, N -acetyl- l -cysteine; NEAA, non-essential amino acids; NS, not significant. Scale bars, 1 mm.

    Techniques Used:

    a , Cell viability measured by CellTiter-Glo of KP -Y and KP -O primary cultures treated for 72 h with 1 µM ISRIB followed by 0.1 µM CB-839 treatment for another 72 h. All values were normalized to their respective vehicle-treated control ( n = 3). b , Cell viability measured by CellTiter-Glo of KP -Y and KP -O (sg Tom or sg Atf4) treated with 0.0625 µM CB-839 for 72 h. All values were normalized to their respective vehicle-treated control ( n = 3). c , Relative viability assessed by CellTiter-Glo of KP- Y and KP -O expressing either control or ATF4 o/e following 0.1 µM CB-839 treatment for 72 h. All values were normalized to their respective vehicle-treated control ( n = 3). d , Anoikis resistance of KP -Y and KP -O treated with either vehicle control, 0.1 µM CB-839, 5 µM BPTES or 2 µM V9302 ( n = 6). e , Anoikis resistance of KP -Y and KP -O treated twice a day for 72 h with 2 μM ISRIB and then seeded in ULA plates with either vehicle, 0.1 µM CB-839, 2 µM ISRIB or a combination of both ( n = 3). f , Correlation analysis between ATF4 expression and CB-839 sensitivity in human lung adenocarcinoma (LUAD) cell lines ( n = 45) from Dependency Map (DepMap) portal. Primary tumor cell lines are depicted with grey squares, metastatic cell lines with pink circles. g-i , KP -Y and KP -O subcutaneously injected in mice. Mice were administered 200 mg/kg CB-839 p.o twice/day every other day for the duration of the experiment once the tumors reached 100 mm 3 in size. Complementary results presented in Fig. and Fig. . g , Endpoint tumor weight after subcutaneous injections of KP -Y and KP -O. h , Lung metastasis burden. i , Left, H&E- stained lung sections showing metastatic foci in the lungs (black and red arrows). Right, close-up of the area identified by the red arrow in the left panel (Scale bars, 1 mm and 100 µm). Data are mean values ± s.e.m. Ordinary one-way ANOVA with Tukey’s multiple comparisons test (a,b,d,e,g,h ), two-way ANOVA ( c ) and simple linear regression ( f ).
    Figure Legend Snippet: a , Cell viability measured by CellTiter-Glo of KP -Y and KP -O primary cultures treated for 72 h with 1 µM ISRIB followed by 0.1 µM CB-839 treatment for another 72 h. All values were normalized to their respective vehicle-treated control ( n = 3). b , Cell viability measured by CellTiter-Glo of KP -Y and KP -O (sg Tom or sg Atf4) treated with 0.0625 µM CB-839 for 72 h. All values were normalized to their respective vehicle-treated control ( n = 3). c , Relative viability assessed by CellTiter-Glo of KP- Y and KP -O expressing either control or ATF4 o/e following 0.1 µM CB-839 treatment for 72 h. All values were normalized to their respective vehicle-treated control ( n = 3). d , Anoikis resistance of KP -Y and KP -O treated with either vehicle control, 0.1 µM CB-839, 5 µM BPTES or 2 µM V9302 ( n = 6). e , Anoikis resistance of KP -Y and KP -O treated twice a day for 72 h with 2 μM ISRIB and then seeded in ULA plates with either vehicle, 0.1 µM CB-839, 2 µM ISRIB or a combination of both ( n = 3). f , Correlation analysis between ATF4 expression and CB-839 sensitivity in human lung adenocarcinoma (LUAD) cell lines ( n = 45) from Dependency Map (DepMap) portal. Primary tumor cell lines are depicted with grey squares, metastatic cell lines with pink circles. g-i , KP -Y and KP -O subcutaneously injected in mice. Mice were administered 200 mg/kg CB-839 p.o twice/day every other day for the duration of the experiment once the tumors reached 100 mm 3 in size. Complementary results presented in Fig. and Fig. . g , Endpoint tumor weight after subcutaneous injections of KP -Y and KP -O. h , Lung metastasis burden. i , Left, H&E- stained lung sections showing metastatic foci in the lungs (black and red arrows). Right, close-up of the area identified by the red arrow in the left panel (Scale bars, 1 mm and 100 µm). Data are mean values ± s.e.m. Ordinary one-way ANOVA with Tukey’s multiple comparisons test (a,b,d,e,g,h ), two-way ANOVA ( c ) and simple linear regression ( f ).

    Techniques Used: Control, Expressing, Injection, Staining

    Related Articles

    Control:

    Article Title: Ageing promotes metastasis via activation of the integrated stress response
    Article Snippet: All transplantation experiments were performed in young immunodeficient NXG hosts to minimize confounding by host age or immunity.All transplantation experiments were performed in young immunodeficient NXG hosts to minimize confounding by host age or immunity.. For CB-839 studies, mice were randomized and subjected to treatment with either 200 mg kg −1 body weight CB-839 (no. HY-12248, MedChemExpress) or vehicle.. Treatments were administered twice a day every other day following either the tumour-establishment phase (subcutaneous implantations) or within 6 h after the bloodstream injection of cells.Treatments were administered twice a day every other day following either the tumour-establishment phase (subcutaneous implantations) or within 6 h after the bloodstream injection of cells.

    Article Title: Aging promotes lung cancer metastasis through epigenetic ATF4 induction
    Article Snippet: For intravenous injections, a total of 5 × 10 4 of the indicated cells were injected into the lateral tail vein of NXG mice.For intravenous injections, a total of 5 × 10 4 of the indicated cells were injected into the lateral tail vein of NXG mice.. For CB-839 studies, mice were randomized and subjected to treatment with either 200 mg/kg body weight CB-839 (#HY-12248, MedChemExpress) or vehicle.. Treatments were administered twice a day every other day following either the tumor-establishment phase (subcutaneous implantations) or within 6 h after the bloodstream injection of cells.Treatments were administered twice a day every other day following either the tumor-establishment phase (subcutaneous implantations) or within 6 h after the bloodstream injection of cells.

    Expressing:

    Article Title: Ageing promotes metastasis via activation of the integrated stress response
    Article Snippet: All transplantation experiments were performed in young immunodeficient NXG hosts to minimize confounding by host age or immunity.All transplantation experiments were performed in young immunodeficient NXG hosts to minimize confounding by host age or immunity.. For CB-839 studies, mice were randomized and subjected to treatment with either 200 mg kg −1 body weight CB-839 (no. HY-12248, MedChemExpress) or vehicle.. Treatments were administered twice a day every other day following either the tumour-establishment phase (subcutaneous implantations) or within 6 h after the bloodstream injection of cells.Treatments were administered twice a day every other day following either the tumour-establishment phase (subcutaneous implantations) or within 6 h after the bloodstream injection of cells.

    Article Title: Aging promotes lung cancer metastasis through epigenetic ATF4 induction
    Article Snippet: For intravenous injections, a total of 5 × 10 4 of the indicated cells were injected into the lateral tail vein of NXG mice.For intravenous injections, a total of 5 × 10 4 of the indicated cells were injected into the lateral tail vein of NXG mice.. For CB-839 studies, mice were randomized and subjected to treatment with either 200 mg/kg body weight CB-839 (#HY-12248, MedChemExpress) or vehicle.. Treatments were administered twice a day every other day following either the tumor-establishment phase (subcutaneous implantations) or within 6 h after the bloodstream injection of cells.Treatments were administered twice a day every other day following either the tumor-establishment phase (subcutaneous implantations) or within 6 h after the bloodstream injection of cells.

    Injection:

    Article Title: Ageing promotes metastasis via activation of the integrated stress response
    Article Snippet: All transplantation experiments were performed in young immunodeficient NXG hosts to minimize confounding by host age or immunity.All transplantation experiments were performed in young immunodeficient NXG hosts to minimize confounding by host age or immunity.. For CB-839 studies, mice were randomized and subjected to treatment with either 200 mg kg −1 body weight CB-839 (no. HY-12248, MedChemExpress) or vehicle.. Treatments were administered twice a day every other day following either the tumour-establishment phase (subcutaneous implantations) or within 6 h after the bloodstream injection of cells.Treatments were administered twice a day every other day following either the tumour-establishment phase (subcutaneous implantations) or within 6 h after the bloodstream injection of cells.

    Article Title: Aging promotes lung cancer metastasis through epigenetic ATF4 induction
    Article Snippet: For intravenous injections, a total of 5 × 10 4 of the indicated cells were injected into the lateral tail vein of NXG mice.For intravenous injections, a total of 5 × 10 4 of the indicated cells were injected into the lateral tail vein of NXG mice.. For CB-839 studies, mice were randomized and subjected to treatment with either 200 mg/kg body weight CB-839 (#HY-12248, MedChemExpress) or vehicle.. Treatments were administered twice a day every other day following either the tumor-establishment phase (subcutaneous implantations) or within 6 h after the bloodstream injection of cells.Treatments were administered twice a day every other day following either the tumor-establishment phase (subcutaneous implantations) or within 6 h after the bloodstream injection of cells.

    Staining:

    Article Title: Ageing promotes metastasis via activation of the integrated stress response
    Article Snippet: All transplantation experiments were performed in young immunodeficient NXG hosts to minimize confounding by host age or immunity.All transplantation experiments were performed in young immunodeficient NXG hosts to minimize confounding by host age or immunity.. For CB-839 studies, mice were randomized and subjected to treatment with either 200 mg kg −1 body weight CB-839 (no. HY-12248, MedChemExpress) or vehicle.. Treatments were administered twice a day every other day following either the tumour-establishment phase (subcutaneous implantations) or within 6 h after the bloodstream injection of cells.Treatments were administered twice a day every other day following either the tumour-establishment phase (subcutaneous implantations) or within 6 h after the bloodstream injection of cells.

    Article Title: Aging promotes lung cancer metastasis through epigenetic ATF4 induction
    Article Snippet: For intravenous injections, a total of 5 × 10 4 of the indicated cells were injected into the lateral tail vein of NXG mice.For intravenous injections, a total of 5 × 10 4 of the indicated cells were injected into the lateral tail vein of NXG mice.. For CB-839 studies, mice were randomized and subjected to treatment with either 200 mg/kg body weight CB-839 (#HY-12248, MedChemExpress) or vehicle.. Treatments were administered twice a day every other day following either the tumor-establishment phase (subcutaneous implantations) or within 6 h after the bloodstream injection of cells.Treatments were administered twice a day every other day following either the tumor-establishment phase (subcutaneous implantations) or within 6 h after the bloodstream injection of cells.

    Labeling:

    Article Title: Ageing promotes metastasis via activation of the integrated stress response
    Article Snippet: All transplantation experiments were performed in young immunodeficient NXG hosts to minimize confounding by host age or immunity.All transplantation experiments were performed in young immunodeficient NXG hosts to minimize confounding by host age or immunity.. For CB-839 studies, mice were randomized and subjected to treatment with either 200 mg kg −1 body weight CB-839 (no. HY-12248, MedChemExpress) or vehicle.. Treatments were administered twice a day every other day following either the tumour-establishment phase (subcutaneous implantations) or within 6 h after the bloodstream injection of cells.Treatments were administered twice a day every other day following either the tumour-establishment phase (subcutaneous implantations) or within 6 h after the bloodstream injection of cells.

    Article Title: Aging promotes lung cancer metastasis through epigenetic ATF4 induction
    Article Snippet: For intravenous injections, a total of 5 × 10 4 of the indicated cells were injected into the lateral tail vein of NXG mice.For intravenous injections, a total of 5 × 10 4 of the indicated cells were injected into the lateral tail vein of NXG mice.. For CB-839 studies, mice were randomized and subjected to treatment with either 200 mg/kg body weight CB-839 (#HY-12248, MedChemExpress) or vehicle.. Treatments were administered twice a day every other day following either the tumor-establishment phase (subcutaneous implantations) or within 6 h after the bloodstream injection of cells.Treatments were administered twice a day every other day following either the tumor-establishment phase (subcutaneous implantations) or within 6 h after the bloodstream injection of cells.

    Derivative Assay:

    Article Title: Ageing promotes metastasis via activation of the integrated stress response
    Article Snippet: All transplantation experiments were performed in young immunodeficient NXG hosts to minimize confounding by host age or immunity.All transplantation experiments were performed in young immunodeficient NXG hosts to minimize confounding by host age or immunity.. For CB-839 studies, mice were randomized and subjected to treatment with either 200 mg kg −1 body weight CB-839 (no. HY-12248, MedChemExpress) or vehicle.. Treatments were administered twice a day every other day following either the tumour-establishment phase (subcutaneous implantations) or within 6 h after the bloodstream injection of cells.Treatments were administered twice a day every other day following either the tumour-establishment phase (subcutaneous implantations) or within 6 h after the bloodstream injection of cells.

    Article Title: Aging promotes lung cancer metastasis through epigenetic ATF4 induction
    Article Snippet: For intravenous injections, a total of 5 × 10 4 of the indicated cells were injected into the lateral tail vein of NXG mice.For intravenous injections, a total of 5 × 10 4 of the indicated cells were injected into the lateral tail vein of NXG mice.. For CB-839 studies, mice were randomized and subjected to treatment with either 200 mg/kg body weight CB-839 (#HY-12248, MedChemExpress) or vehicle.. Treatments were administered twice a day every other day following either the tumor-establishment phase (subcutaneous implantations) or within 6 h after the bloodstream injection of cells.Treatments were administered twice a day every other day following either the tumor-establishment phase (subcutaneous implantations) or within 6 h after the bloodstream injection of cells.

    Luciferase:

    Article Title: Ageing promotes metastasis via activation of the integrated stress response
    Article Snippet: All transplantation experiments were performed in young immunodeficient NXG hosts to minimize confounding by host age or immunity.All transplantation experiments were performed in young immunodeficient NXG hosts to minimize confounding by host age or immunity.. For CB-839 studies, mice were randomized and subjected to treatment with either 200 mg kg −1 body weight CB-839 (no. HY-12248, MedChemExpress) or vehicle.. Treatments were administered twice a day every other day following either the tumour-establishment phase (subcutaneous implantations) or within 6 h after the bloodstream injection of cells.Treatments were administered twice a day every other day following either the tumour-establishment phase (subcutaneous implantations) or within 6 h after the bloodstream injection of cells.

    Article Title: Aging promotes lung cancer metastasis through epigenetic ATF4 induction
    Article Snippet: For intravenous injections, a total of 5 × 10 4 of the indicated cells were injected into the lateral tail vein of NXG mice.For intravenous injections, a total of 5 × 10 4 of the indicated cells were injected into the lateral tail vein of NXG mice.. For CB-839 studies, mice were randomized and subjected to treatment with either 200 mg/kg body weight CB-839 (#HY-12248, MedChemExpress) or vehicle.. Treatments were administered twice a day every other day following either the tumor-establishment phase (subcutaneous implantations) or within 6 h after the bloodstream injection of cells.Treatments were administered twice a day every other day following either the tumor-establishment phase (subcutaneous implantations) or within 6 h after the bloodstream injection of cells.

    Ex Vivo:

    Article Title: Ageing promotes metastasis via activation of the integrated stress response
    Article Snippet: All transplantation experiments were performed in young immunodeficient NXG hosts to minimize confounding by host age or immunity.All transplantation experiments were performed in young immunodeficient NXG hosts to minimize confounding by host age or immunity.. For CB-839 studies, mice were randomized and subjected to treatment with either 200 mg kg −1 body weight CB-839 (no. HY-12248, MedChemExpress) or vehicle.. Treatments were administered twice a day every other day following either the tumour-establishment phase (subcutaneous implantations) or within 6 h after the bloodstream injection of cells.Treatments were administered twice a day every other day following either the tumour-establishment phase (subcutaneous implantations) or within 6 h after the bloodstream injection of cells.

    Article Title: Aging promotes lung cancer metastasis through epigenetic ATF4 induction
    Article Snippet: For intravenous injections, a total of 5 × 10 4 of the indicated cells were injected into the lateral tail vein of NXG mice.For intravenous injections, a total of 5 × 10 4 of the indicated cells were injected into the lateral tail vein of NXG mice.. For CB-839 studies, mice were randomized and subjected to treatment with either 200 mg/kg body weight CB-839 (#HY-12248, MedChemExpress) or vehicle.. Treatments were administered twice a day every other day following either the tumor-establishment phase (subcutaneous implantations) or within 6 h after the bloodstream injection of cells.Treatments were administered twice a day every other day following either the tumor-establishment phase (subcutaneous implantations) or within 6 h after the bloodstream injection of cells.

    In Vivo Imaging:

    Article Title: Ageing promotes metastasis via activation of the integrated stress response
    Article Snippet: All transplantation experiments were performed in young immunodeficient NXG hosts to minimize confounding by host age or immunity.All transplantation experiments were performed in young immunodeficient NXG hosts to minimize confounding by host age or immunity.. For CB-839 studies, mice were randomized and subjected to treatment with either 200 mg kg −1 body weight CB-839 (no. HY-12248, MedChemExpress) or vehicle.. Treatments were administered twice a day every other day following either the tumour-establishment phase (subcutaneous implantations) or within 6 h after the bloodstream injection of cells.Treatments were administered twice a day every other day following either the tumour-establishment phase (subcutaneous implantations) or within 6 h after the bloodstream injection of cells.

    Article Title: Aging promotes lung cancer metastasis through epigenetic ATF4 induction
    Article Snippet: For intravenous injections, a total of 5 × 10 4 of the indicated cells were injected into the lateral tail vein of NXG mice.For intravenous injections, a total of 5 × 10 4 of the indicated cells were injected into the lateral tail vein of NXG mice.. For CB-839 studies, mice were randomized and subjected to treatment with either 200 mg/kg body weight CB-839 (#HY-12248, MedChemExpress) or vehicle.. Treatments were administered twice a day every other day following either the tumor-establishment phase (subcutaneous implantations) or within 6 h after the bloodstream injection of cells.Treatments were administered twice a day every other day following either the tumor-establishment phase (subcutaneous implantations) or within 6 h after the bloodstream injection of cells.



    Similar Products

    96
    MedChemExpress body weight cb 839
    a , Schematic of [1,2- 13 C]- d -glucose tracing in glycolysis (blue circles) or the pentose phosphate pathway (PPP) (grey circles). b , c , Fractions of labelled pyruvate ( b ) and lactate ( c ) from [1,2- 13 C]- d -glucose in KP -Y and KP -O ( n = 6). d , Schematic of [U 13 C]- l -glutamine tracing (pink circles). e , Mass isotopomer analysis of glutamate (Glu), fumarate (Fum), citrate (Cit) and aspartate (Asp) from [U 13 C]- l -glutamine tracing in KP -Y ( n = 6) and KP -O ( n = 4). f , g , Oxygen consumption rate (OCR) ( f ) and extracellular acidification rate (ECAR) ( g ) in KP -Y ( n = 10) and KP -O ( n = 11). h , i , Mass isotopomer analysis of indicated TCA intermediates from [U 13 C]- l -glutamine tracing in KP -Y, KP -O, KP -Y sh Atf4 .2, KP -O sh Atf4 .2 ( h ) and in KP -Y; KP -Y ATF4 o/e; KP -O and KP -O ATF4 o/e ( i ) ( n = 4 per condition). j , Relative viability of KP -Y and KP -O treated <t>with</t> <t>CB-839</t> ( n = 3) k , Heatmap of relative viability for KP -Y and KP -O treated with 0.1 μM CB-839 and the indicated compounds. All data points are relative to vehicle (Veh)-treated controls ( n = 3). l , Anoikis resistance of KP -Y; KP -Y ATF4 o/e; KP -O and KP -O ATF4 o/e treated with 0.1 μM CB-839 for 48 h ( n = 3). m , Heatmap of anoikis resistance of KP -Y and KP -O treated with 0.1 μM CB-839 and the indicated compounds. All data points are relative to vehicle-treated controls ( n = 3). n , o , Lung metastasis burden measured by means of bioluminescence ( n ) or H&E quantification ( o ) (with representative images) in mice after intravenous injections of KP -Y and KP -O and treated with CB-839 or vehicle ( n = 4, 3, 4, 5). p , q , Longitudinal tumour growth of subcutaneous tumours ( KP -Y n = 24, KP -Y + CB-839 n = 22, KP -O n = 26 and KP -O + CB-839 n = 18 tumours) ( p ) and H&E quantification of lung metastases foci ( n = 12, 11, 13 and 9 mice, respectively) ( q ). Mice were administered CB-839 once the tumours reached 100 mm 3 in size. Data are mean ± s.e.m. Two-sided multiple unpaired t -tests ( b , c , e – i , q ), two-way ANOVA ( j , p ), one-way ANOVA with Tukey’s multiple comparisons test ( l , n , o ). 5ME-THF, 5-methyltetrahydrofolate; NAC, N -acetyl- l -cysteine; NEAA, non-essential amino acids; NS, not significant. Scale bars, 1 mm.
    Body Weight Cb 839, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/body+weight+cb+839/Telaglenastat/pmc13128440-218-16-21
    Average 96 stars, based on 1 article reviews
    body weight cb 839 - by Bioz Stars, 2026-09
    96/100 stars
      Buy from Supplier

    Image Search Results


    a , Schematic of [1,2- 13 C]- d -glucose tracing in glycolysis (blue circles) or the pentose phosphate pathway (PPP) (grey circles). b , c , Fractions of labelled pyruvate ( b ) and lactate ( c ) from [1,2- 13 C]- d -glucose in KP -Y and KP -O ( n = 6). d , Schematic of [U 13 C]- l -glutamine tracing (pink circles). e , Mass isotopomer analysis of glutamate (Glu), fumarate (Fum), citrate (Cit) and aspartate (Asp) from [U 13 C]- l -glutamine tracing in KP -Y ( n = 6) and KP -O ( n = 4). f , g , Oxygen consumption rate (OCR) ( f ) and extracellular acidification rate (ECAR) ( g ) in KP -Y ( n = 10) and KP -O ( n = 11). h , i , Mass isotopomer analysis of indicated TCA intermediates from [U 13 C]- l -glutamine tracing in KP -Y, KP -O, KP -Y sh Atf4 .2, KP -O sh Atf4 .2 ( h ) and in KP -Y; KP -Y ATF4 o/e; KP -O and KP -O ATF4 o/e ( i ) ( n = 4 per condition). j , Relative viability of KP -Y and KP -O treated with CB-839 ( n = 3) k , Heatmap of relative viability for KP -Y and KP -O treated with 0.1 μM CB-839 and the indicated compounds. All data points are relative to vehicle (Veh)-treated controls ( n = 3). l , Anoikis resistance of KP -Y; KP -Y ATF4 o/e; KP -O and KP -O ATF4 o/e treated with 0.1 μM CB-839 for 48 h ( n = 3). m , Heatmap of anoikis resistance of KP -Y and KP -O treated with 0.1 μM CB-839 and the indicated compounds. All data points are relative to vehicle-treated controls ( n = 3). n , o , Lung metastasis burden measured by means of bioluminescence ( n ) or H&E quantification ( o ) (with representative images) in mice after intravenous injections of KP -Y and KP -O and treated with CB-839 or vehicle ( n = 4, 3, 4, 5). p , q , Longitudinal tumour growth of subcutaneous tumours ( KP -Y n = 24, KP -Y + CB-839 n = 22, KP -O n = 26 and KP -O + CB-839 n = 18 tumours) ( p ) and H&E quantification of lung metastases foci ( n = 12, 11, 13 and 9 mice, respectively) ( q ). Mice were administered CB-839 once the tumours reached 100 mm 3 in size. Data are mean ± s.e.m. Two-sided multiple unpaired t -tests ( b , c , e – i , q ), two-way ANOVA ( j , p ), one-way ANOVA with Tukey’s multiple comparisons test ( l , n , o ). 5ME-THF, 5-methyltetrahydrofolate; NAC, N -acetyl- l -cysteine; NEAA, non-essential amino acids; NS, not significant. Scale bars, 1 mm.

    Journal: Nature

    Article Title: Ageing promotes metastasis via activation of the integrated stress response

    doi: 10.1038/s41586-026-10216-0

    Figure Lengend Snippet: a , Schematic of [1,2- 13 C]- d -glucose tracing in glycolysis (blue circles) or the pentose phosphate pathway (PPP) (grey circles). b , c , Fractions of labelled pyruvate ( b ) and lactate ( c ) from [1,2- 13 C]- d -glucose in KP -Y and KP -O ( n = 6). d , Schematic of [U 13 C]- l -glutamine tracing (pink circles). e , Mass isotopomer analysis of glutamate (Glu), fumarate (Fum), citrate (Cit) and aspartate (Asp) from [U 13 C]- l -glutamine tracing in KP -Y ( n = 6) and KP -O ( n = 4). f , g , Oxygen consumption rate (OCR) ( f ) and extracellular acidification rate (ECAR) ( g ) in KP -Y ( n = 10) and KP -O ( n = 11). h , i , Mass isotopomer analysis of indicated TCA intermediates from [U 13 C]- l -glutamine tracing in KP -Y, KP -O, KP -Y sh Atf4 .2, KP -O sh Atf4 .2 ( h ) and in KP -Y; KP -Y ATF4 o/e; KP -O and KP -O ATF4 o/e ( i ) ( n = 4 per condition). j , Relative viability of KP -Y and KP -O treated with CB-839 ( n = 3) k , Heatmap of relative viability for KP -Y and KP -O treated with 0.1 μM CB-839 and the indicated compounds. All data points are relative to vehicle (Veh)-treated controls ( n = 3). l , Anoikis resistance of KP -Y; KP -Y ATF4 o/e; KP -O and KP -O ATF4 o/e treated with 0.1 μM CB-839 for 48 h ( n = 3). m , Heatmap of anoikis resistance of KP -Y and KP -O treated with 0.1 μM CB-839 and the indicated compounds. All data points are relative to vehicle-treated controls ( n = 3). n , o , Lung metastasis burden measured by means of bioluminescence ( n ) or H&E quantification ( o ) (with representative images) in mice after intravenous injections of KP -Y and KP -O and treated with CB-839 or vehicle ( n = 4, 3, 4, 5). p , q , Longitudinal tumour growth of subcutaneous tumours ( KP -Y n = 24, KP -Y + CB-839 n = 22, KP -O n = 26 and KP -O + CB-839 n = 18 tumours) ( p ) and H&E quantification of lung metastases foci ( n = 12, 11, 13 and 9 mice, respectively) ( q ). Mice were administered CB-839 once the tumours reached 100 mm 3 in size. Data are mean ± s.e.m. Two-sided multiple unpaired t -tests ( b , c , e – i , q ), two-way ANOVA ( j , p ), one-way ANOVA with Tukey’s multiple comparisons test ( l , n , o ). 5ME-THF, 5-methyltetrahydrofolate; NAC, N -acetyl- l -cysteine; NEAA, non-essential amino acids; NS, not significant. Scale bars, 1 mm.

    Article Snippet: For CB-839 studies, mice were randomized and subjected to treatment with either 200 mg kg −1 body weight CB-839 (no. HY-12248, MedChemExpress) or vehicle.

    Techniques:

    a , Cell viability measured by CellTiter-Glo of KP -Y and KP -O primary cultures treated for 72 h with 1 µM ISRIB followed by 0.1 µM CB-839 treatment for another 72 h. All values were normalized to their respective vehicle-treated control ( n = 3). b , Cell viability measured by CellTiter-Glo of KP -Y and KP -O (sg Tom or sg Atf4) treated with 0.0625 µM CB-839 for 72 h. All values were normalized to their respective vehicle-treated control ( n = 3). c , Relative viability assessed by CellTiter-Glo of KP- Y and KP -O expressing either control or ATF4 o/e following 0.1 µM CB-839 treatment for 72 h. All values were normalized to their respective vehicle-treated control ( n = 3). d , Anoikis resistance of KP -Y and KP -O treated with either vehicle control, 0.1 µM CB-839, 5 µM BPTES or 2 µM V9302 ( n = 6). e , Anoikis resistance of KP -Y and KP -O treated twice a day for 72 h with 2 μM ISRIB and then seeded in ULA plates with either vehicle, 0.1 µM CB-839, 2 µM ISRIB or a combination of both ( n = 3). f , Correlation analysis between ATF4 expression and CB-839 sensitivity in human lung adenocarcinoma (LUAD) cell lines ( n = 45) from Dependency Map (DepMap) portal. Primary tumor cell lines are depicted with grey squares, metastatic cell lines with pink circles. g-i , KP -Y and KP -O subcutaneously injected in mice. Mice were administered 200 mg/kg CB-839 p.o twice/day every other day for the duration of the experiment once the tumors reached 100 mm 3 in size. Complementary results presented in Fig. and Fig. . g , Endpoint tumor weight after subcutaneous injections of KP -Y and KP -O. h , Lung metastasis burden. i , Left, H&E- stained lung sections showing metastatic foci in the lungs (black and red arrows). Right, close-up of the area identified by the red arrow in the left panel (Scale bars, 1 mm and 100 µm). Data are mean values ± s.e.m. Ordinary one-way ANOVA with Tukey’s multiple comparisons test (a,b,d,e,g,h ), two-way ANOVA ( c ) and simple linear regression ( f ).

    Journal: Nature

    Article Title: Ageing promotes metastasis via activation of the integrated stress response

    doi: 10.1038/s41586-026-10216-0

    Figure Lengend Snippet: a , Cell viability measured by CellTiter-Glo of KP -Y and KP -O primary cultures treated for 72 h with 1 µM ISRIB followed by 0.1 µM CB-839 treatment for another 72 h. All values were normalized to their respective vehicle-treated control ( n = 3). b , Cell viability measured by CellTiter-Glo of KP -Y and KP -O (sg Tom or sg Atf4) treated with 0.0625 µM CB-839 for 72 h. All values were normalized to their respective vehicle-treated control ( n = 3). c , Relative viability assessed by CellTiter-Glo of KP- Y and KP -O expressing either control or ATF4 o/e following 0.1 µM CB-839 treatment for 72 h. All values were normalized to their respective vehicle-treated control ( n = 3). d , Anoikis resistance of KP -Y and KP -O treated with either vehicle control, 0.1 µM CB-839, 5 µM BPTES or 2 µM V9302 ( n = 6). e , Anoikis resistance of KP -Y and KP -O treated twice a day for 72 h with 2 μM ISRIB and then seeded in ULA plates with either vehicle, 0.1 µM CB-839, 2 µM ISRIB or a combination of both ( n = 3). f , Correlation analysis between ATF4 expression and CB-839 sensitivity in human lung adenocarcinoma (LUAD) cell lines ( n = 45) from Dependency Map (DepMap) portal. Primary tumor cell lines are depicted with grey squares, metastatic cell lines with pink circles. g-i , KP -Y and KP -O subcutaneously injected in mice. Mice were administered 200 mg/kg CB-839 p.o twice/day every other day for the duration of the experiment once the tumors reached 100 mm 3 in size. Complementary results presented in Fig. and Fig. . g , Endpoint tumor weight after subcutaneous injections of KP -Y and KP -O. h , Lung metastasis burden. i , Left, H&E- stained lung sections showing metastatic foci in the lungs (black and red arrows). Right, close-up of the area identified by the red arrow in the left panel (Scale bars, 1 mm and 100 µm). Data are mean values ± s.e.m. Ordinary one-way ANOVA with Tukey’s multiple comparisons test (a,b,d,e,g,h ), two-way ANOVA ( c ) and simple linear regression ( f ).

    Article Snippet: For CB-839 studies, mice were randomized and subjected to treatment with either 200 mg kg −1 body weight CB-839 (no. HY-12248, MedChemExpress) or vehicle.

    Techniques: Control, Expressing, Injection, Staining